Advertisement
ICCC vs NKTX
Which Stock Would AI Choose? ImmuCell Corporation (ICCC) vs. Nkarta, Inc. (NKTX) Stock Comparison
Key Takeaways
- ICCC is a revenue-generating animal health company, while NKTX is a pre-revenue clinical-stage biotechnology firm, making their risk profiles fundamentally different.
- ICCC recently reported a 46% year-over-year jump in preliminary third-quarter sales, reflecting strong domestic demand for its calf-health products.
- NKTX is building toward a 2026 clinical data readout for its lead cell-therapy program, a catalyst that could reshape sentiment but carries substantial uncertainty.
- Both stocks are small-capitalization names, but ICCC trades near the upper end of its 52-week range while NKTX has weakened sharply in recent weeks.
- Analyst coverage is sparse for ICCC but concentrated and generally positive for NKTX, highlighting the difference in how each is followed by Wall Street.
- For more details on each company's latest developments and daily price action, explore ICCC Major News and ICCC Today's Price Move, as well as NKTX Major News and NKTX Today's Price Move.
- To see how automated strategies are currently positioning across the market, explore the Trending AI Robots.
Introduction
This stock comparison examines two very different small-capitalization companies: ICCC, an animal health business generating growing revenue, and NKTX, a clinical-stage biotech still years from commercialization. Investors weighing a stable, commercially established operation against a high-risk, catalyst-driven pipeline may find this relative performance analysis useful. Because these companies operate in unrelated sectors with contrasting financial profiles, the comparison is less about direct competition and more about contrasting market positioning, risk tolerance, and what each stock offers in the current environment.
ICCC Overview and Recent Performance
ICCC, or ImmuCell Corporation, develops and manufactures animal health products for dairy and beef cattle, led by its First Defense and Tri-Shield franchises that help prevent scours (a serious intestinal disease) in newborn calves. Recent market activity has been supported by accelerating commercial momentum: the company reported preliminary third-quarter 2026 sales of roughly $8.0 million, a 46% increase from the prior-year quarter, with domestic sales up about 29%.
Across its product lines, Tri-Shield sales rose 51%, Dual-Force grew 36%, and its functional feed line advanced 37% year over year. Management has attributed the gains to restored product availability, expanded sales territories, and a favorable domestic calf market, and it has outlined a capacity expansion intended to more than triple current output. Shares have climbed substantially from their 52-week low, though the stock remains lightly covered by sell-side analysts and still trades on a premium valuation relative to its modest earnings base.
NKTX Overview and Recent Performance
NKTX, or Nkarta, Inc., is a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies — treatments that use modified immune cells — for autoimmune diseases through its lead candidate NKX019. The company is enrolling patients in two dose-escalation studies, Ntrust-1 and Ntrust-2, and has expanded protocols to allow outpatient dosing and add rheumatoid arthritis. Initial clinical data are expected in 2026.
Financially, NKTX generates no product revenue, funding operations from a cash position of roughly $266.7 million as of March 31, 2026, which management expects to extend into 2029. Recent quarterly losses have been in the tens of millions of dollars, typical of the biotech investment phase. The shares have pulled back meaningfully in recent weeks and trade near the lower portion of their 52-week range, even as most covering analysts maintain buy ratings with price targets well above current levels. Sentiment remains tied to upcoming clinical readouts and execution risk.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's AI trading bots, chosen for their fit with current market conditions. Tickeron offers hundreds of AI trading bots that collectively trade thousands of different tickers, each built around distinct trading styles, strategies, timeframes, performance statistics, and watchlists. Rather than surfacing every available bot, this section highlights only those demonstrating characteristics most suitable for the present market environment. Traders can review performance metrics and strategy details to identify approaches that align with their own objectives. Explore the Trending AI Robots to see which automated strategies are currently standing out.
Head-to-Head Comparison
The clearest contrast between these two names is commercial maturity. ICCC generates tangible, growing revenue and has moved toward profitability, giving it a steadier fundamental base and less dependence on a single event. Its risks center on manufacturing capacity, gross-margin variability, international sales softness, and a limited product portfolio.
NKTX, by contrast, is a binary-outcome investment whose value hinges largely on clinical data. It offers significant potential upside if trials succeed, but also meaningful downside risk, ongoing cash burn, and dilution considerations. Sector exposure differs sharply as well: ICCC sits in defensive-leaning animal health, while NKTX is exposed to volatile biotech sentiment. On recent momentum, ICCC has shown upward price strength alongside improving fundamentals, whereas NKTX has declined despite favorable analyst coverage — a divergence that underscores how differently these stocks respond to catalysts and risk appetite.
Tickeron AI Verdict
Based on observable trend consistency, stability, and relative positioning, Tickeron's AI would likely favor ICCC in the current environment. Its combination of accelerating sales, improving operating trends, and a stock trading near the higher end of its range suggests more constructive, durable momentum. NKTX carries higher potential upside but relies on forward-looking clinical catalysts and is presently in a weaker technical state. The assessment is probabilistic rather than definitive, reflecting the distinct risk-reward profiles of a commercial-stage animal health firm versus a pre-revenue biotech awaiting pivotal data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ICCC is a Hold and NKTX is a Hold.
ICCC in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 05, 2026
ICCC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 38 cases where ICCC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 58 cases where ICCC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on ICCC as a result. In 90 of 122 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
ICCC moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ICCC crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +4.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICCC advanced for three days, in 185 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 113 of 140 cases where ICCC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for ICCC moved out of overbought territory on October 14, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 20 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Moving Average Convergence Divergence Histogram (MACD) for ICCC turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 33 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICCC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. ICCC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.837) is normal, around the industry mean (3.498). ICCC has a moderately high P/E Ratio (122.500) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (8.610) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.847) is also within normal values, averaging (440.869).
NKTX sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for NKTX moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for NKTX crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NKTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for NKTX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for NKTX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 66 cases where NKTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for NKTX just turned positive on November 04, 2026. Looking at past instances where NKTX's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Following a +13.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where NKTX advanced for three days, in 208 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
NKTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.500) is normal, around the industry mean (3.498). P/E Ratio (-1.088) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. NKTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ICCC | NKTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 85 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | 37 Fair valued | |
PROFIT vs RISK RATING 1..100 | 91 | 100 | |
SMR RATING 1..100 | 88 | 97 | |
PRICE GROWTH RATING 1..100 | 42 | 84 | |
P/E GROWTH RATING 1..100 | 2 | 14 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NKTX's Valuation (37) in the null industry is somewhat better than the same rating for ICCC (100) in the Medical Specialties industry. This means that NKTX’s stock grew somewhat faster than ICCC’s over the last 12 months.
ICCC's Profit vs Risk Rating (91) in the Medical Specialties industry is in the same range as NKTX (100) in the null industry. This means that ICCC’s stock grew similarly to NKTX’s over the last 12 months.
ICCC's SMR Rating (88) in the Medical Specialties industry is in the same range as NKTX (97) in the null industry. This means that ICCC’s stock grew similarly to NKTX’s over the last 12 months.
ICCC's Price Growth Rating (42) in the Medical Specialties industry is somewhat better than the same rating for NKTX (84) in the null industry. This means that ICCC’s stock grew somewhat faster than NKTX’s over the last 12 months.
ICCC's P/E Growth Rating (2) in the Medical Specialties industry is in the same range as NKTX (14) in the null industry. This means that ICCC’s stock grew similarly to NKTX’s over the last 12 months.
| ICCC | NKTX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 87% | 2 days ago 82% |
| Stochastic ODDS (%) | 2 days ago 78% | 2 days ago 86% |
| Momentum ODDS (%) | 2 days ago 74% | N/A |
| MACD ODDS (%) | 2 days ago 72% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 77% | 2 days ago 87% |
| TrendMonth ODDS (%) | 2 days ago 76% | 2 days ago 87% |
| Advances ODDS (%) | 2 days ago 77% | 8 days ago 84% |
| Declines ODDS (%) | 6 days ago 71% | 2 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 84% | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ICCC’s FA Score shows that 1 FA rating(s) are green while NKTX’s FA Score has 1 green FA rating(s).
- ICCC’s FA Score: 1 green, 4 red.
- NKTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ICCC’s TA Score shows that 7 TA indicator(s) are bullish while NKTX’s TA Score has 5 bullish TA indicator(s).
- ICCC’s TA Score: 7 bullish, 3 bearish.
- NKTX’s TA Score: 5 bullish, 4 bearish.
Price Growth
ICCC (@Biotechnology) experienced а +0.10% price change this week, while NKTX (@Biotechnology) price change was -11.76% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
ICCC is expected to report earnings on Nov 12, 2026.
NKTX is expected to report earnings on Mar 25, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ICCC and
Correlation & Price change
A.I.dvisor indicates that over the last year, ICCC has been loosely correlated with NKTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ICCC jumps, then NKTX could also see price increases.
| Ticker / NAME | Correlation To ICCC | 1D Price Change % | ||
|---|---|---|---|---|
| ICCC | 100% | +0.39% | ||
| NKTX - ICCC | 43% Loosely correlated | -15.09% | ||
| JANX - ICCC | 27% Poorly correlated | -5.64% | ||
| BOLT - ICCC | 26% Poorly correlated | -2.02% | ||
| NERV - ICCC | 24% Poorly correlated | -5.32% | ||
| IMMP - ICCC | 23% Poorly correlated | -8.95% | ||
More | ||||
NKTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, NKTX has been loosely correlated with CRSP. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if NKTX jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To NKTX | 1D Price Change % | ||
|---|---|---|---|---|
| NKTX | 100% | -15.09% | ||
| CRSP - NKTX | 49% Loosely correlated | -9.77% | ||
| EDIT - NKTX | 47% Loosely correlated | -8.91% | ||
| PROK - NKTX | 45% Loosely correlated | -3.48% | ||
| VIR - NKTX | 45% Loosely correlated | -3.63% | ||
| RNAC - NKTX | 45% Loosely correlated | -1.85% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PCR | 17.85 | N/A | N/A |
| Simplify VettaFi Private Credit Strategy ETF (PCR) | |||
| MMIT | 23.84 | -0.06 | -0.25% |
| NYLIM MacKay Muni Intermediate ETF (MMIT) | |||
| TDSC | 28.06 | -0.14 | -0.49% |
| ETC Cabana Target Drawdown 10 ETF (TDSC) | |||
| BCPL | 23.98 | -0.17 | -0.68% |
| BNY Mellon Core Plus ETF (BCPL) | |||
| WAR | 25.46 | -0.29 | -1.12% |
| U.S. Global Technology and Aerospace and Defense ETF | |||